MedTrace Logo

Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia

NCT00003688 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-10

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of dactinomycin in treating patients who have persistent or recurrent gestational trophoblastic neoplasia.

Conditions

  • Gestational Trophoblastic Tumor

Interventions

BIOLOGICAL

dactinomycin

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • Allan Covens, MD · Toronto Sunnybrook Regional Cancer Centre

Study Design

Purpose
TREATMENT

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Primary Completion
2006-09-30

Countries

  • United States
  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003688 on ClinicalTrials.gov